NCT03520972View on ClinicalTrials.gov

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

July 29, 2019

Study Completion Date

July 29, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PB-119 75ug

60 eligible patients will be included in this group

DRUG

PB-119 150ug

60 eligible patients will be included in this group

DRUG

PB-119 200ug

60 eligible patients will be included in this group

DRUG

placebo

60 eligible patients will be included in this group

Trial Locations (1)

100000

Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

PegBio Co., Ltd.

OTHER

NCT03520972 - Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects | Biotech Hunter | Biotech Hunter